Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Functional Genome Profiling to Understand Cancer Immune Responsiveness.

Wang E, Bedognetti D, Marincola FM.

Methods Mol Biol. 2020;2055:231-244. doi: 10.1007/978-1-4939-9773-2_11.

PMID:
31502155
2.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I.

Immunity. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. No abstract available.

3.

Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.

Isnaldi E, Ferraioli D, Ferrando L, Brohée S, Ferrando F, Fregatti P, Bedognetti D, Ballestrero A, Zoppoli G.

Breast Cancer Res Treat. 2019 Oct;177(3):773. doi: 10.1007/s10549-019-05348-z.

PMID:
31300923
4.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

5.

Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.

Isnaldi E, Ferraioli D, Ferrando L, Brohée S, Ferrando F, Fregatti P, Bedognetti D, Ballestrero A, Zoppoli G.

Breast Cancer Res Treat. 2019 Sep;177(2):335-343. doi: 10.1007/s10549-019-05313-w. Epub 2019 Jun 20. Erratum in: Breast Cancer Res Treat. 2019 Jul 12;:.

PMID:
31222709
6.

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod.

Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S.

Sci Rep. 2019 Jun 12;9(1):8572. doi: 10.1038/s41598-019-42784-9.

7.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

8.

Monoallelic expression in melanoma.

Silcock L, Almabrazi H, Mokrab Y, Jithesh P, Al-Hashmi M, James N, Mathew R, Mattei V, Bedognetti D, Lessi F, Temanni R, Seliger B, Al-Ali R, Marincola FM, Wang E, Tomei S.

J Transl Med. 2019 Apr 5;17(1):112. doi: 10.1186/s12967-019-1863-x.

9.

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD.

Oncoimmunology. 2018 Jul 30;7(10):e1490854. doi: 10.1080/2162402X.2018.1490854. eCollection 2018.

10.

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.

Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola FM, Viens P, Mamessier E, Ceccarelli M, Birnbaum D, Bedognetti D.

Br J Cancer. 2018 Nov;119(11):1383-1391. doi: 10.1038/s41416-018-0309-1. Epub 2018 Oct 24.

PMID:
30353048
11.

Evolution of Metastases in Space and Time under Immune Selection.

Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, Buttard B, Morgand E, Bruni D, Jouret-Mourin A, Hubert C, Kartheuser A, Humblet Y, Ceccarelli M, Syed N, Marincola FM, Bedognetti D, Van den Eynde M, Galon J.

Cell. 2018 Oct 18;175(3):751-765.e16. doi: 10.1016/j.cell.2018.09.018. Epub 2018 Oct 11.

PMID:
30318143
12.

How can nanotechnology help the fight against breast cancer?

Avitabile E, Bedognetti D, Ciofani G, Bianco A, Delogu LG.

Nanoscale. 2018 Jul 5;10(25):11719-11731. doi: 10.1039/c8nr02796j. Review.

PMID:
29917035
13.

Immune oncology, immune responsiveness and the theory of everything.

Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J.

J Immunother Cancer. 2018 Jun 5;6(1):50. doi: 10.1186/s40425-018-0355-5.

14.

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.

Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J.

Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018. Review.

15.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I.

Immunity. 2018 Apr 17;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023. Epub 2018 Apr 5. Erratum in: Immunity. 2019 Aug 20;51(2):411-412.

16.

A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification.

Roelands J, Decock J, Boughorbel S, Rinchai D, Maccalli C, Ceccarelli M, Black M, Print C, Chou J, Presnell S, Quinn C, Jithesh P, Syed N, Al Bader SBJ, Bedri S, Wang E, Marincola FM, Chaussabel D, Kuppen P, Miller LD, Bedognetti D, Hendrickx W.

Version 2. F1000Res. 2017 Mar 20 [revised 2018 Jan 1];6:296. doi: 10.12688/f1000research.10960.2. eCollection 2017.

17.

Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.

Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola FM, Bedognetti D, Hendrickx W.

Int J Mol Sci. 2017 Oct 24;18(10). pii: E2229. doi: 10.3390/ijms18102229. Review.

18.

Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells.

Orecchioni M, Bedognetti D, Newman L, Fuoco C, Spada F, Hendrickx W, Marincola FM, Sgarrella F, Rodrigues AF, Ménard-Moyon C, Cesareni G, Kostarelos K, Bianco A, Delogu LG.

Nat Commun. 2017 Oct 24;8(1):1109. doi: 10.1038/s41467-017-01015-3.

19.

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.

Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G.

J Transl Med. 2017 Oct 2;15(1):199. doi: 10.1186/s12967-017-1296-3.

20.

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

Maccalli C, Giannarelli D, Chiarucci C, Cutaia O, Giacobini G, Hendrickx W, Amato G, Annesi D, Bedognetti D, Altomonte M, Danielli R, Calabrò L, Di Giacomo AM, Marincola FM, Parmiani G, Maio M.

Oncoimmunology. 2017 May 8;6(7):e1323618. doi: 10.1080/2162402X.2017.1323618. eCollection 2017.

21.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.

Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D.

Oncoimmunology. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. eCollection 2017.

22.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.

Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL Jr.

Oncoimmunology. 2016 Oct 18;5(12):e1240857. doi: 10.1080/2162402X.2016.1240857. eCollection 2016.

23.

Conservation of immune gene signatures in solid tumors and prognostic implications.

Chifman J, Pullikuth A, Chou JW, Bedognetti D, Miller LD.

BMC Cancer. 2016 Nov 22;16(1):911.

24.

Checkpoint Inhibitors and Their Application in Breast Cancer.

Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B.

Breast Care (Basel). 2016 Apr;11(2):108-15. doi: 10.1159/000445335. Epub 2016 Apr 26. Review.

25.

Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype.

Jin P, Zhao Y, Liu H, Chen J, Ren J, Jin J, Bedognetti D, Liu S, Wang E, Marincola F, Stroncek D.

Sci Rep. 2016 May 23;6:26345. doi: 10.1038/srep26345.

26.

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.

Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM.

Cancer Immunol Res. 2016 Jul;4(7):600-10. doi: 10.1158/2326-6066.CIR-15-0149. Epub 2016 Apr 28.

27.

Harnessing the immune system for the treatment of melanoma: current status and future prospects.

Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D.

Expert Rev Clin Immunol. 2016 Aug;12(8):879-93. doi: 10.1080/1744666X.2016.1176529. Epub 2016 May 3. Review.

PMID:
27070898
28.

Disentangling the relationship between tumor genetic programs and immune responsiveness.

Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B.

Curr Opin Immunol. 2016 Apr;39:150-8. doi: 10.1016/j.coi.2016.02.001. Epub 2016 Mar 9. Review.

PMID:
26967649
29.

Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.

Cocca M, Bedognetti D, La Bianca M, Gasparini P, Girotto G.

J Transl Med. 2016 Jan 22;14:22. doi: 10.1186/s12967-016-0778-z.

30.

Molecular and Genomic Impact of Large and Small Lateral Dimension Graphene Oxide Sheets on Human Immune Cells from Healthy Donors.

Orecchioni M, Jasim DA, Pescatori M, Manetti R, Fozza C, Sgarrella F, Bedognetti D, Bianco A, Kostarelos K, Delogu LG.

Adv Healthc Mater. 2016 Jan 21;5(2):276-87. doi: 10.1002/adhm.201500606. Epub 2015 Dec 20.

PMID:
26687729
31.

Prognostic and predictive immune gene signatures in breast cancer.

Bedognetti D, Hendrickx W, Marincola FM, Miller LD.

Curr Opin Oncol. 2015 Nov;27(6):433-44. doi: 10.1097/CCO.0000000000000234. Review.

PMID:
26418235
32.

Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus.

Ascierto ML, Bozzano F, Bedognetti D, Marras F, Schechterly C, Matsuura K, Picciotto A, Marenco S, Zhao Y, DeGiorgi V, Sommariva M, Moretta L, Wang E, Alter HJ, Marincola FM, De Maria A.

J Transl Med. 2015 Mar 1;13:77. doi: 10.1186/s12967-015-0428-x.

33.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

Clin Cancer Res. 2015 Jun 15;21(12):2840-50. doi: 10.1158/1078-0432.CCR-14-2777. Epub 2015 Feb 23.

34.

Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome.

Bedognetti D, Wang E, Marincola FM.

Oncoimmunology. 2014 Apr 9;3:e28727. eCollection 2014. No abstract available.

35.

The perception of nanotechnology and nanomedicine: a worldwide social media study.

Sechi G, Bedognetti D, Sgarrella F, Van Eperen L, Marincola FM, Bianco A, Delogu LG.

Nanomedicine (Lond). 2014 Jul;9(10):1475-86. doi: 10.2217/nnm.14.78.

PMID:
25253496
36.

The immune-related role of BRAF in melanoma.

Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, Al Hashmi M, Ascierto ML, Liu Q, Ayotte BD, Worschech A, Uccellini L, Ascierto PA, Stroncek D, Palmieri G, Chouchane L, Wang E, Marincola FM.

Mol Oncol. 2015 Jan;9(1):93-104. doi: 10.1016/j.molonc.2014.07.014. Epub 2014 Aug 6.

37.

Impact of carbon nanotubes and graphene on immune cells.

Orecchioni M, Bedognetti D, Sgarrella F, Marincola FM, Bianco A, Delogu LG.

J Transl Med. 2014 May 21;12:138. doi: 10.1186/1479-5876-12-138. Review.

38.

Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.

Jin P, Civini S, Zhao Y, De Giorgi V, Ren J, Sabatino M, Jin J, Wang H, Bedognetti D, Marincola F, Stroncek D.

Br J Cancer. 2014 Jun 10;110(12):2955-64. doi: 10.1038/bjc.2014.235. Epub 2014 May 8.

39.

Melanoma NOS1 expression promotes dysfunctional IFN signaling.

Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingluff CL Jr, Lee PP, Rosenberg SA, Alter H, Yao K, Wang E, Marincola FM.

J Clin Invest. 2014 May;124(5):2147-59. Epub 2014 Apr 1.

40.

Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.

Tomei S, Wang E, Delogu LG, Marincola FM, Bedognetti D.

Expert Opin Biol Ther. 2014 May;14(5):663-86. doi: 10.1517/14712598.2014.890586. Epub 2014 Mar 13. Review.

PMID:
24625306
41.

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.

Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, Sommariva M, Sertoli MR, Simon R, Wang E, Rosenberg SA, Marincola FM.

Br J Cancer. 2013 Oct 29;109(9):2412-23. doi: 10.1038/bjc.2013.557. Epub 2013 Oct 15.

42.

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Galon J, Angell HK, Bedognetti D, Marincola FM.

Immunity. 2013 Jul 25;39(1):11-26. doi: 10.1016/j.immuni.2013.07.008. Review.

43.

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes.

Murtas D, Maric D, De Giorgi V, Reinboth J, Worschech A, Fetsch P, Filie A, Ascierto ML, Bedognetti D, Liu Q, Uccellini L, Chouchane L, Wang E, Marincola FM, Tomei S.

Br J Cancer. 2013 Jul 9;109(1):76-82. doi: 10.1038/bjc.2013.335. Epub 2013 Jun 27.

44.

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.

Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH.

J Transl Med. 2013 Jun 12;11:145. doi: 10.1186/1479-5876-11-145.

45.

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.

Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.

Nature. 2013 Jun 27;498(7455):506-10. doi: 10.1038/nature12199. Epub 2013 Jun 2.

46.

Prediction of response to anticancer immunotherapy using gene signatures.

Wang E, Bedognetti D, Marincola FM.

J Clin Oncol. 2013 Jul 1;31(19):2369-71. doi: 10.1200/JCO.2013.49.2157. Epub 2013 May 28. No abstract available.

PMID:
23715576
47.

Common pathways to tumor rejection.

Wang E, Bedognetti D, Tomei S, Marincola FM.

Ann N Y Acad Sci. 2013 May;1284:75-9. doi: 10.1111/nyas.12063.

PMID:
23651198
48.

Functionalized carbon nanotubes as immunomodulator systems.

Pescatori M, Bedognetti D, Venturelli E, Ménard-Moyon C, Bernardini C, Muresu E, Piana A, Maida G, Manetti R, Sgarrella F, Bianco A, Delogu LG.

Biomaterials. 2013 Jun;34(18):4395-403. doi: 10.1016/j.biomaterials.2013.02.052. Epub 2013 Mar 16.

PMID:
23507086
49.

Functionalized multiwalled carbon nanotubes as ultrasound contrast agents.

Delogu LG, Vidili G, Venturelli E, Ménard-Moyon C, Zoroddu MA, Pilo G, Nicolussi P, Ligios C, Bedognetti D, Sgarrella F, Manetti R, Bianco A.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16612-7. doi: 10.1073/pnas.1208312109. Epub 2012 Sep 24.

50.

Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.

Bedognetti D, Ansaldi F, Zanardi E, Durando P, Sertoli MR, Massucco C, Balleari E, Racchi O, Zoppoli G, Orsi A, Alicino C, Icardi G, Marincola FM, Zupo S, Ferrarini M, De Maria A.

Blood. 2012 Aug 30;120(9):1954-7. No abstract available.

Supplemental Content

Loading ...
Support Center